Format

Send to

Choose Destination
Chest. 2008 Jun;133(6 Suppl):234S-256S. doi: 10.1378/chest.08-0673.

New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Author information

1
From the Henderson Research Center, McMaster University, Hamilton, ON, Canada. Electronic address: jweitz@thrombosis.hhscr.org.
2
From the Henderson Research Center, McMaster University, Hamilton, ON, Canada.
3
Hôtel-Dieu University Hospital, Paris, France.

Erratum in

  • Chest. 2008 Aug;134(2):473.

Abstract

This chapter focuses on new antithrombotic drugs that are in phase II or III clinical testing. Development of these new agents was prompted by limitations of existing antiplatelet, anticoagulant, or fibrinolytic drugs. Addressing these unmet needs, this chapter (1) outlines the rationale for development of new antithrombotic agents, (2) describes the new antiplatelet, anticoagulant, and fibrinolytic drugs, and (3) provides clinical perspectives on the opportunities and challenges faced by these novel agents.

PMID:
18574267
DOI:
10.1378/chest.08-0673
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center